Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia

Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytok...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Adriana Seber, Claudio Galvão de CastroJunior, Lucila N. Kerbauy, Alexandre V. Hirayama, Carmem Bonfim, Juliana Folloni Fernandes, Mair Souza, Rony Schafell, Samir Nabhan, Sandra Regina Loggetto, Belinda Pinto Simões, Vanderson Rocha, Marcos de Lima, Renato L. Guerino-Cunha, Henrique Bittencourt
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Cellular therapy Car-T cells Immunotherapy Adoptive cellular therapy Advanced cellular therapy Acute lymphoblastic leukemia Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/47a011b41a24447fbfbe666a71b1e194
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia

Ejemplares similares